Drug Profile
C 1205
Alternative Names: C-1205Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator ConjuGon
- Developer Atterx Biotherapeutics
- Class Antibacterials
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Urinary tract infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Urinary-tract-infections(Prevention) in USA
- 10 Jan 2011 Phase-I clinical trials in Urinary tract infections in USA (unspecified route)